Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes

V. Vlková, I. Štěpánek, V. Hrušková, F. Šenigl, V. Mayerová, M. Šrámek, J. Šímová, J. Bieblová, M. Indrová, T. Hejhal, N. Dérian, D. Klatzmann, A. Six, M. Reiniš,

. 2014 ; 5 (16) : 6923-6935.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023195

Grantová podpora
NT14461 MZ0 CEP - Centrální evidence projektů

Downregulation of MHC class I expression on tumour cells, a common mechanism by which tumour cells can escape from specific immune responses, can be associated with coordinated silencing of antigen-presenting machinery genes. The expression of these genes can be restored by IFNγ. In this study we documented association of DNA demethylation of selected antigen-presenting machinery genes located in the MHC genomic locus (TAP-1, TAP-2, LMP-2, LMP-7) upon IFNγ treatment with MHC class I upregulation on tumour cells in several MHC class I-deficient murine tumour cell lines (TC-1/A9, TRAMP-C2, MK16 and MC15). Our data also documented higher methylation levels in these genes in TC-1/A9 cells, as compared to their parental MHC class I-positive TC-1 cells. IFNγ-mediated DNA demethylation was relatively fast in comparison with demethylation induced by DNA methyltransferase inhibitor 5-azacytidine, and associated with increased histone H3 acetylation in the promoter regions of APM genes. Comparative transcriptome analysis in distinct MHC class I-deficient cell lines upon their treatment with either IFNγ or epigenetic agents revealed that a set of genes, significantly enriched for the antigen presentation pathway, was regulated in the same manner. Our data demonstrate that IFNγ acts as an epigenetic modifier when upregulating the expression of antigen-presenting machinery genes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023195
003      
CZ-PrNML
005      
20190703132804.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.2222 $2 doi
035    __
$a (PubMed)25071011
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vlková, Veronika $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague.
245    10
$a Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes / $c V. Vlková, I. Štěpánek, V. Hrušková, F. Šenigl, V. Mayerová, M. Šrámek, J. Šímová, J. Bieblová, M. Indrová, T. Hejhal, N. Dérian, D. Klatzmann, A. Six, M. Reiniš,
520    9_
$a Downregulation of MHC class I expression on tumour cells, a common mechanism by which tumour cells can escape from specific immune responses, can be associated with coordinated silencing of antigen-presenting machinery genes. The expression of these genes can be restored by IFNγ. In this study we documented association of DNA demethylation of selected antigen-presenting machinery genes located in the MHC genomic locus (TAP-1, TAP-2, LMP-2, LMP-7) upon IFNγ treatment with MHC class I upregulation on tumour cells in several MHC class I-deficient murine tumour cell lines (TC-1/A9, TRAMP-C2, MK16 and MC15). Our data also documented higher methylation levels in these genes in TC-1/A9 cells, as compared to their parental MHC class I-positive TC-1 cells. IFNγ-mediated DNA demethylation was relatively fast in comparison with demethylation induced by DNA methyltransferase inhibitor 5-azacytidine, and associated with increased histone H3 acetylation in the promoter regions of APM genes. Comparative transcriptome analysis in distinct MHC class I-deficient cell lines upon their treatment with either IFNγ or epigenetic agents revealed that a set of genes, significantly enriched for the antigen presentation pathway, was regulated in the same manner. Our data demonstrate that IFNγ acts as an epigenetic modifier when upregulating the expression of antigen-presenting machinery genes.
650    _2
$a zvířata $7 D000818
650    _2
$a prezentace antigenu $x genetika $7 D017951
650    12
$a metylace DNA $7 D019175
650    _2
$a down regulace $7 D015536
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a fibrosarkom $x genetika $x imunologie $x metabolismus $7 D005354
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    12
$a geny MHC třídy I $7 D005805
650    _2
$a interferon gama $x genetika $x imunologie $x metabolismus $7 D007371
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a signální transdukce $7 D015398
650    _2
$a transfekce $7 D014162
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Štěpánek, Ivan $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague.
700    1_
$a Hrušková, Veronika $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague. $7 xx0228115
700    1_
$a Šenigl, Filip $u Department of Viral and Cellular Genetics, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague. $7 xx0134659
700    1_
$a Mayerová, Veronika $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague. $7 _AN069575
700    1_
$a Šrámek, Martin $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague.
700    1_
$a Šímová, Jana $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague. $7 xx0119399
700    1_
$a Bieblová, Jana $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague. $7 xx0127729
700    1_
$a Indrová, Marie $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague. $7 xx0069868
700    1_
$a Hejhal, Tomáš $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague.
700    1_
$a Dérian, Nicolas $u UPMC Univ Paris 06, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; CNRS, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, CIC-BTi Biotherapy & Département Hospitalo-Universitaire (DHU) Inflammation-Immunopathology-Biotherapy (i2B), Paris, France.
700    1_
$a Klatzmann, David $u UPMC Univ Paris 06, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; CNRS, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, CIC-BTi Biotherapy & Département Hospitalo-Universitaire (DHU) Inflammation-Immunopathology-Biotherapy (i2B), Paris, France.
700    1_
$a Six, Adrien $u UPMC Univ Paris 06, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; CNRS, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, CIC-BTi Biotherapy & Département Hospitalo-Universitaire (DHU) Inflammation-Immunopathology-Biotherapy (i2B), Paris, France.
700    1_
$a Reiniš, Milan $u Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague. $7 xx0083033
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 5, č. 16 (2014), s. 6923-6935
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25071011 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20190703132954 $b ABA008
999    __
$a ok $b bmc $g 1083533 $s 906188
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 5 $c 16 $d 6923-6935 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NT14461 $p MZ0
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace